Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vertex Pharmaceuticals (VRTX)

Vertex director Suketu Upadhyay will not stand for re-election; board to shrink to 10

Neutral Impact 2 of 5 leadership Written later

Vertex director Suketu Upadhyay told the board on April 28, 2026 that he will not stand for re-election at the 2026 annual meeting of shareholders. He has been named the forthcoming Chief Financial Officer of Incyte Corporation, and the company said his decision was due to scheduling conflicts and did not involve any disagreement with Vertex. The board intends to reduce its size to ten members after his departure.

Key points

  • Upadhyay informed the board on April 28, 2026 of his decision not to stand for re-election at the 2026 annual meeting.
  • He will continue to serve on the board until the 2026 annual meeting.
  • He has been named the forthcoming Chief Financial Officer of Incyte Corporation.
  • The board intends to reduce its size to ten members; the company said the slate of remaining nominees is otherwise unchanged.

The filing

CompanyVertex Pharmaceuticals (VRTX)
Form8-K, current report
Filed with the SECApr 29, 2026, 4:05 PM ET
Accession number0000875320-26-000166

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.